Intertek partners with CrystecPharma to advance formulation science and accelerate development timelines for dry powder inhaler products
11 Dec 2024
Cambridge, UK: Intertek, a leading Total Quality Assurance provider to industries worldwide, is pleased to announce that it has entered a partnership with CrystecPharma, focusing on advancing formulation science and accelerating development timelines for inhaled medicines, particularly dry powder inhaler (DPI) products.
Initially developed for asthma and chronic obstructive pulmonary disease, DPIs provide direct drug delivery to the lungs, enabling rapid action and lower doses than more conventional oral administration. As well as other respiratory diseases, DPIs are now being explored for other applications including treatment of bacterial lung infections, delivery of vaccines, and systemic drugs like insulin.
For over 30 years, Intertek has actively contributed to the future of orally inhaled and nasal drug products through its Centre of Excellence for the development of these medicines at its Cambridge, UK, campus.
CrystecPharma is a crystal and particle engineering company which applies its proprietary ‘mSAS®’ (modified Supercritical Anti-Solvent) drug formulation technology to improve the performance of medicines. The technique allows many molecules that are traditionally challenging to formulate as powders to be developed in this way. CrystecPharma also has a unique set-up that means formulation and process development can occur in a matter of weeks.
The two companies will develop a “fast to clinic” platform to support pharmaceutical clients with rapid DPI development, from the initial formulation concept to GMP clinical manufacturing, in less than half the time typically required. This highly agile, rapid framework will allow clients aiming to formulate small or large (biologics) molecules, or to repurpose existing active pharmaceutical ingredients, to benefit from technology which enables new forms of molecules to be crystallised and novel particles to be manufactured in ways that greatly enhance their therapeutic performance.
Chris Vernall, Intertek Commercial Director, said: “Combining the proprietary mSAS® technology and the speed of early development that partnering with CrystecPharma affords, with the GMP manufacturing and analytics expertise at Intertek, provides the market with an unparalleled service in this area. This unique platform will enable highly effective, stable and safe DPI medicines to be developed and brought to market in a fraction of the time previously possible.’’
Paul Thorning, co-founder and Chief Executive Officer of CrystecPharma, shared: “The strength of our award-winning mSAS® technology and Intertek’s expertise in analytical development and GMP clinical manufacturing creates unique opportunities to develop innovative, high-performing medicines and improved treatments for patients.”
The platform, available from January 2025, is underpinned by Intertek’s deep experience in developing robust analytical methods for inhaled drug product quality, expertise in device selection and performance testing, and flexible approach to scalable GMP clinical manufacturing.
Find out more about Inhalation Drug Development Services
For Media Information:
Please contact:
Lorna Kettle
ECA Marketing Director, Intertek Pharmaceutical Services
+44 (0) 116 296 1620
lorna.kettle@intertek.com
About CrystecPharma
CrystecPharma (Crystec Ltd), founded in 2007, and headquartered in Bradford, West Yorkshire, is a crystal and particle engineering company applying its proprietary and award-winning mSAS® (modified Supercritical Anti-Solvent) technology to enable drug molecules to be crystallised in new forms and novel particles to be manufactured in ways that greatly enhance their therapeutic performance, thereby transforming the quality of life for many patients. Crystec’s multi-disciplinary team has extensive experience working with the global pharmaceutical and health care industry and has pioneered the application of supercritical fluid technology to the rapid development of high-performing small and large molecule drugs. Crystec is also developing its own innovative therapies in important areas of unmet clinical need, including women’s health, urology and treating respiratory disease. To find out more visit www.crystecpharma.com or email us at info@crystecpharma.com
About Intertek Pharmaceutical Services
Intertek’s pharmaceutical services locations include Melbourn, Cambridge (UK), Manchester (UK), Basel (Switzerland), Whitehouse, (New Jersey, USA), Mumbai (India) and Melbourne, (Australia). www.intertek.com/pharmaceutical
About Intertek
Intertek is a leading Total Quality Assurance provider to industries worldwide.
Our network of more than 1,000 laboratories and offices in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers' operations and supply chains.
Intertek is a purpose-led company to Bring Quality, Safety and Sustainability to Life. We provide 24/7 mission-critical quality assurance solutions to our clients to ensure that they can operate with well-functioning supply chains in each of their operations.
Our Customer Promise is: Intertek Total Quality Assurance expertise, delivered consistently, with precision, pace and passion, enabling our customers to power ahead safely.
intertek.com